FibroBiologics FBLG 深 沪
已收盘 11-13 16:00:00 美东时间
0.9271
-0.041
-4.21%
华盛通- 最 高1.04
- 今 开1.02
- 成交量 3.56万股
- 最 低 0.92
- 昨 收 0.9678
- 总市值 656.54万
- 52周最高 9.598
- 市盈率 静 --
- 换手率 0.50%
- 52周最低 0.6201
- 委 比 71.99%
- 总股本 708.17万
- 历史最高 1100.00
- 量 比 0.62
- 振 幅 12.40%
- 历史最低 0.6201
- 每 手 1
- 风险率 2.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FibroBiologics Announces Update On Its Intellectual Property Portfolio
Portfolio Extends Its Lead in Fibroblast Intellectual Property With 170 Issued Patents and 325+ Patents Issued and Pending Portfolio Covers the Therapeutic Use of Fibroblasts Across Multiple...
11-12 21:30
FibroBiologics Secures European Patent Covering Methods Of Preparing Fibroblasts To Home To Tumors And Carry Oncolytic Viruses And Other Anti-Cancer Agents
HOUSTON, Nov. 5, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived m...
11-05 21:35
FibroBiologics Says IP Australia Issues Notice Of Acceptance For Australian Patent Application Titled ‘Cellular Blend For The Regeneration Of Chondrocytes Or Cartilage Type Cells’
Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and Improve the Condition of Degenerated and Aged Discs HOUSTON, Oct. 14, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBio...
10-14 20:35
EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections
FibroBiologics Inc. (NASDAQ:FBLG) on Wednesday filed a U.S. patent application for a cell-based platform designed to produce therapeutic peptides continuously inside the human body, offering a potential long-term alternative to traditional weight-loss and diabetes treatments. Cellular Innovation For...
10-07 20:15
FibroBiologics Receives European Patent Titled Methods Of Enhancing Fibroblast Therapeutic Activity
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today anno...
09-29 20:36
FibroBiologics Completes ATM Private Placement Of 298,508 Shares And Warrants At $1.675 Per Unit To Its Chief Scientific Officer
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today annou...
09-17 20:41
FibroBiologics Announces Insider Private Placement Financing
FibroBiologics, Inc. ( ($FBLG) ) just unveiled an announcement. On September 15...
09-15 19:49
FibroBiologics Secures US Patent For Therapeutic Use Of Fibroblasts For Use In Wound Healing
Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of Wounds HOUSTON, Sept. 3, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ p...
09-03 20:37
FibroBiologics Releases Third cGMP CYWC628 Drug Product Batch For Shipment To Australia, Supporting Ongoing Phase 1/2 Diabetic Foot Ulcer Trial
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today annou...
08-27 20:34
FibroBiologics Regains Compliance with Nasdaq Trading Rules
HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending wi...
08-26 20:30
